Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3,2-h]acridin-7-one analogues of acronycine

被引:81
作者
Costes, N
Le Deit, H
Michel, S
Tillequin, F
Koch, M
Pfeiffer, B
Renard, P
Léonce, S
Guilbaud, N
Kraus-Berthier, L
Pierré, A
Atassi, G
机构
[1] Univ Paris 05, Lab Pharmacognosie, Fac Sci Pharmaceut & Biol, CNRS,UMR 8638, F-75006 Paris, France
[2] ADIR & Compagnie, F-92415 Courbevoie, France
[3] Inst Rech Servier, Div Cancerol Expt, F-92150 Suresnes, France
关键词
D O I
10.1021/jm990972l
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Benzo[b]acronycine (6-methoxy-3,3,14-trimethyl-3,14-dihydro-7H-benzo[b]pyrano[3,2-h]acridin-7-one, 4), an acronycine analogue with an additional aromatic ring linearly fused on the natural alkaloid basic skeleton, was synthesized in three steps, starting from 3-amino-2-naphthalenecarboxylic acid (5). Eight 1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine esters and diesters (17-24) were obtained by catalytic osmic oxidation, followed by acylation. All these compounds were significantly more cytotoxic than acronycine, when tested against L1210 leukemia cells in vitro. The potency of the cyclic carbonate 24 was in the range of the most active drugs currently used in cancer chemotherapy. Two selected diesters (17 and 24) were evaluated in vivo against P388 leukemia and colon 38 adenocarcinoma implanted in mice. Both compounds were markedly active at doses 16-fold lower than the dose of acronycine itself. Against colon 38 adenocarcinoma, compounds 17 and 24 were highly efficient, inhibiting tumor growth by more than 80%. Diacetate 17 was the most active, inhibiting tumor growth by 96% at 6.25 mg/kg, with two of seven mice being tumor-free on day 43.
引用
收藏
页码:2395 / 2402
页数:8
相关论文
共 33 条
  • [1] ACRONYCINE EPOXIDE - A NEW ACRIDONE ALKALOID FROM SEVERAL SARCOMELICOPE SPECIES
    BRUMBOUSQUET, M
    MITAKU, S
    SKALTSOUNIS, AL
    TILLEQUIN, F
    KOCH, M
    [J]. PLANTA MEDICA, 1988, (05) : 470 - 471
  • [2] Cheng C C, 1988, Prog Med Chem, V25, P35, DOI 10.1016/S0079-6468(08)70277-7
  • [3] Chiral dihydroxylation of acronycine:: Absolute configuration of natural cis-1,2-dihydroxy-1,2-dihydroacronycine and cytotoxicity of (1R,2R)- and (1S,2S)-1,2-diacetoxy-1,2-dihydroacronycine
    Costes, N
    Michel, S
    Tillequin, F
    Koch, M
    Pierré, A
    Atassi, G
    [J]. JOURNAL OF NATURAL PRODUCTS, 1999, 62 (03): : 490 - 492
  • [4] DORR R T, 1988, Journal of Drug Development, V1, P31
  • [5] DORR RT, 1989, CANCER RES, V49, P340
  • [6] Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series
    Elomri, A
    Mitaku, S
    Michel, S
    Skaltsounis, AL
    Tillequin, F
    Koch, M
    Pierre, A
    Guilbaud, N
    Leonce, S
    KrausBerthier, L
    Rolland, Y
    Atassi, G
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (24) : 4762 - 4766
  • [7] INTRAMOLECULAR NUCLEOPHILIC-ADDITION OF PHENOLATE TO UNACTIVATED DOUBLE AND TRIPLE BONDS - RELATIVE REACTIVITY, REGIOSPECIFICITY, STEREOCHEMISTRY, AND MECHANISM
    EVANS, CM
    KIRBY, AJ
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1984, (07): : 1269 - 1275
  • [8] Analysis of structural requirements for Ah receptor antagonist activity: Ellipticines, flavones, and related compounds
    Gasiewicz, TA
    Kende, AS
    Rucci, G
    Whitney, B
    Willey, JJ
    [J]. BIOCHEMICAL PHARMACOLOGY, 1996, 52 (11) : 1787 - 1803
  • [9] GIMENEZARNAU E, 1988, ANTI-CANCER DRUG DES, V13, P431
  • [10] CRYSTAL AND MOLECULAR STRUCTURE OF BROMDIHYDROACRONYCINE
    GOUGOUTA.JZ
    KASKI, BA
    [J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, 1970, B 26 : 853 - &